基于循环蛋白标志物组合的肺癌风险评估
该研究利用CARET队列样本开发基于4种循环蛋白(CA125、CEA、CYFRA 21-1、Pro-SFTPB)的肺癌风险评分,并在EPIC和NSHDS队列中盲法验证。
要点
- 基于4种循环蛋白的生物标志物评分可提升肺癌风险预测区分度。
- 整合模型在验证集中AUC达0.83,优于吸烟模型的0.73。
- 在USPSTF筛查标准特异度0.83时,整合模型敏感度为0.63。
核心结论
- 循环蛋白标志物组合可改善肺癌风险评估,并可能用于定义CT筛查资格。
研究设计与样本
- 利用CARET队列108例1年内确诊的吸烟肺癌患者和216例匹配对照开发基于4种蛋白的生物标志物风险评分。
- 在EPIC和NSHDS两个欧洲人群队列的63例1年内确诊的吸烟肺癌患者和90例匹配对照中盲法验证。
主要发现
- 基于USPSTF筛查标准总体特异度0.83时,整合模型敏感度为0.63,吸烟模型为0.43。
- 基于USPSTF筛查标准总体敏感度0.42时,整合模型特异度为0.95,吸烟模型为0.86。
关键数值与推荐
- 生物标志物评分基于CA125、CEA、CYFRA 21-1和Pro-SFTPB四种循环蛋白。
- 验证集平均年龄57.7岁(SD 8.7),男性占68.6%。
临床怎么用
- 该生物标志物组合有望辅助识别可从CT筛查中获益的吸烟人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is an urgent need to improve lung cancer risk assessment because current screening criteria miss a large proportion of cases. OBJECTIVE: To investigate whether a lung cancer risk prediction model based on a panel of selected circulating protein biomarkers can outperform a traditional risk prediction model and current US screening criteria. DESIGN, SETTING, AND PARTICIPANTS: Prediagnostic samples from 108 ever-smoking patients with lung cancer diagnosed within 1 year after blood collection and samples from 216 smoking-matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were used to develop a biomarker risk score based on 4 proteins (cancer antigen 125 [CA125], carcinoembryonic antigen [CEA], cytokeratin-19 fragment [CYFRA 21-1], and the precursor form of surfactant protein B [Pro-SFTPB]). The biomarker score was subsequently validated blindly using absolute risk estimates among 63 ever-smoking patients with lung cancer diagnosed within 1 year after blood collection and 90 matched controls from 2 large European population-based cohorts, the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Northern Sweden Health and Disease Study (NSHDS). MAIN OUTCOMES AND MEASURES: Model validity in discriminating between future lung cancer cases and controls. Discrimination estimates were weighted to reflect the background populations of EPIC and NSHDS validation studies (area under the receiver-operating characteristics curve [AUC], sensitivity, and specificity). RESULTS: In the validation study of 63 ever-smoking patients with lung cancer and 90 matched controls (mean [SD] age, 57.7 [8.7] years; 68.6% men) from EPIC and NSHDS, an integrated risk prediction model that combined smoking exposure with the biomarker score yielded an AUC of 0.83 (95% CI, 0.76-0.90) compared with 0.73 (95% CI, 0.64-0.82) for a model based on smoking exposure alone (P = .003 for difference in AUC). At an overall specificity of 0.83, based on the US Preventive Services Task Force screening criteria, the sensitivity of the integrated risk prediction (biomarker) model was 0.63 compared with 0.43 for the smoking model. Conversely, at an overall sensitivity of 0.42, based on the US Preventive Services Task Force screening criteria, the integrated risk prediction model yielded a specificity of 0.95 compared with 0.86 for the smoking model. CONCLUSIONS AND RELEVANCE: This study provided a proof of principle in showing that a panel of circulating protein biomarkers may improve lung cancer risk assessment and may be used to define eligibility for computed tomography screening.
引用
- Guida F, Sun N, Bantis LE, et al. Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. JAMA Oncol. 2018. PMID: 30003238. doi:10.1001/jamaoncol.2018.2078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。